Response to Comments: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

This document is a response-to-comments notice for the Local Coverage Determination DL39270 / L39270 concerning allogeneic hematopoietic cell transplantation for primary refractory or relapsed Hodgkin's and Non-Hodgkin's lymphoma of B- or T-cell origin. It records the comment period (2022-03-31 to 2022-05-14), notice start (2022-07-21), and effective date (2022-09-04) but does not itself state clinical coverage criteria, limitations, or frequency limits; refer to LCD L39270 for detailed coverage rules.

"This document is a response to comments for Local Coverage Determination DL39270 / L39270 concerning allogeneic hematopoietic cell transplantation for primary refractory or relapsed Hodgkin's and N..."

Sign up to see full coverage criteria, indications, and limitations.